Table of Contents
Just under 10 million people died of cancer in 2022, according to the Global Cancer Observatory. That single figure flattens a very uneven picture. Some cancers are caught early and cured with surgery and a short course of treatment. Others announce themselves late, spread fast, and still resist most of what oncology can throw at them.
Ranking cancers by how many people they kill is a blunt instrument, but a useful one. It shows where screening genuinely changes outcomes, where treatment gaps remain widest, and where research money does the most good.
Death toll versus deadliness: two different rankings
Before the list, one distinction worth holding onto. A cancer can top a mortality table for two reasons: it is very common, or it is very hard to cure. Often it is both.
Lung cancer leads on volume and on lethality. Prostate cancer, by contrast, is the most commonly diagnosed cancer in men in many countries yet causes a fraction of the deaths that lung cancer does. Pancreatic cancer sits lower on total deaths simply because fewer people get it, not because it has become easier to treat. Five-year survival in the United States is still around 13%.
The figures below are GLOBOCAN 2022 estimates and reflect global deaths.
1. Lung cancer: about 1.8 million deaths a year
No other cancer comes close. Lung cancer kills more people than colorectal, liver and breast cancer combined, and five-year survival in the US hovers near 25%. The main reason is timing: most cases are found after the tumour has already spread.
Smoking still drives the majority of cases, and the risk climbs with pack-years rather than with how long ago someone quit. Around 10% to 20% of lung cancers in the US occur in people who never smoked, where radon, air pollution, asbestos and secondhand smoke are the usual suspects. Low-dose CT screening for heavy smokers aged 50 to 80 cuts lung cancer deaths by roughly 20% in trials, yet fewer than one in five eligible Americans actually gets scanned.
2. Colorectal cancer: about 900,000 deaths
This is the cancer where early detection has the clearest payoff. Five-year survival is around 65% overall, but it jumps to roughly 91% when the disease is confined to the colon. Screening does something better than catch cancer early, though: it removes precancerous polyps before they ever turn malignant.
Guidelines in the US now start screening at 45, a decade earlier than they did until recently, because incidence in adults under 50 has been climbing by 1% to 2% a year for three decades. Nobody has a clean explanation yet. Diets heavy in processed meat, obesity, alcohol and sedentary work are the usual candidates.
3. Liver cancer: about 760,000 deaths
Liver cancer is unusual in that most cases have a known cause. Chronic hepatitis B and C, heavy alcohol use, and metabolic dysfunction-associated fatty liver disease account for the overwhelming majority. Survival is bleak, around 20% at five years in the US, partly because early disease causes almost no symptoms.
For people already known to have cirrhosis, six-monthly ultrasound with or without a blood alpha-fetoprotein test is the standard surveillance. Antiviral treatment for hepatitis B and the new generation of direct-acting drugs for hepatitis C sharply reduce the risk of progression, which makes liver cancer one of the more preventable entries on this list.
4. Breast cancer: about 670,000 deaths
Breast cancer is the most commonly diagnosed cancer worldwide, with around 2.3 million new cases in 2022, so it appears here largely because of volume. Where mammography and modern treatment are available, five-year survival sits near 90%. In parts of sub-Saharan Africa it can fall below 50%, and the gap is almost entirely about how late women present.
Inherited BRCA1 and BRCA2 mutations explain 5% to 10% of cases. Alcohol intake, postmenopausal weight gain and long-term hormone exposure nudge risk upward, while breastfeeding and physical activity nudge it down.
5. Stomach cancer: about 660,000 deaths
Rates have fallen steadily in most wealthy countries over the past half-century, largely thanks to refrigeration, which cut reliance on salted and smoked foods. It remains common in East Asia, Eastern Europe and parts of South America.
Helicobacter pylori infection is the single biggest modifiable factor. Eradicating it with a short course of antibiotics lowers stomach cancer risk substantially, and Japan and South Korea run population screening programmes that catch tumours while they are still operable. In the US, five-year survival is around 36%, mostly because the disease is found late.
6. Pancreatic cancer: about 467,000 deaths
Fewer cases, brutal outcomes. Only about a fifth of pancreatic tumours are operable at diagnosis, and five-year survival sits near 13%. The pancreas sits deep behind the stomach, so tumours grow quietly until they block a bile duct or press on a nerve. New-onset diabetes in someone over 50, jaundice, unexplained weight loss and persistent mid-back pain are the signals worth chasing.
This is also where desperation gets exploited. People facing a diagnosis with a 13% survival figure are prime targets for clinics selling unproven protocols, which is a pattern traced in this history of how health misinformation went mainstream. Coffee enemas and restrictive diets do not shrink pancreatic tumours, and delays while trying them can cost the window for chemotherapy.
7. Oesophageal cancer: about 450,000 deaths
Two distinct diseases share one name. Squamous cell carcinoma, linked to smoking, alcohol and very hot drinks, dominates in parts of Asia and East Africa. Adenocarcinoma, linked to chronic reflux, Barrett’s oesophagus and obesity, has risen sharply in the UK, US and Australia since the 1970s.
Difficulty swallowing is usually a late symptom, and by then the tumour has often invaded surrounding tissue. Five-year survival in the US is around 21%. For people with long-standing reflux, endoscopy can detect Barrett’s changes before cancer develops.
What actually moves the death toll
Most of these numbers are not fixed. Where countries have attacked the causes and improved early detection, mortality has fallen.
Screening that works
Low-dose CT for heavy smokers, colonoscopy and stool tests from 45, mammography, cervical screening, and ultrasound surveillance for people with cirrhosis. Each has a measurable effect on deaths, and each depends on people actually showing up. That turnout is sensitive to what people read online, and influencer-driven health misinformation has made a measurable dent in screening confidence in some communities.
Vaccines that prevent cancer outright
HPV vaccination has pushed cervical cancer rates in young women in the UK and Australia down by around 90% in the cohorts vaccinated as teenagers. Childhood hepatitis B vaccination in Taiwan cut liver cancer in children by more than half. Both are rare examples of a genuine cancer vaccine, and neither requires anyone to change their diet.
Symptoms worth a conversation
- A cough lasting more than three weeks, or coughing blood
- Blood in stool, or a persistent change in bowel habits
- Unexplained weight loss of more than 5% in a few months
- New jaundice, or pale stools with dark urine
- Difficulty swallowing solids that was not there months ago
- New-onset diabetes after 50, especially with back pain
None of these guarantees cancer, and most turn out to be something else. The point is that the cancers near the top of this list are the ones where a four-week delay matters most.
The wellness industry has built a large business around prevention, selling supplements, detoxes and elaborate longevity optimisation protocols that have far less evidence behind them than a colonoscopy at 45 or a nicotine patch. Nobody gets a viral moment for quitting smoking, which is roughly why the least glamorous interventions remain the ones that save the most lives.
